These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6869411)

  • 1. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis.
    Runge LA
    Am J Med; 1983 Jul; 75(1A):52-6. PubMed ID: 6869411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole.
    Husain Z; Runge LA
    J Rheumatol; 1980; 7(6):825-30. PubMed ID: 6451692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goldsalts, levamisole and D-penicillamine as first choice slow-acting antirheumatic drugs in rheumatoid arthritis--a long-term follow-up study.
    Veys EM; Mielants H; Verbruggen G
    Clin Exp Rheumatol; 1987; 5(2):111-6. PubMed ID: 3608266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
    J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levamisole - a possible alternative to gold and penicillamine in the longterm treatment of rheumatoid arthritis?
    Capell HA; Hunter JA; Rennie JA; Murdoch RM
    J Rheumatol; 1981; 8(5):730-40. PubMed ID: 7310774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods.
    Situnayake RD; Grindulis KA; McConkey B
    Ann Rheum Dis; 1987 Mar; 46(3):177-83. PubMed ID: 2883939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
    Jiang L; Zhao N; Ni L
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Jun; 23(3):213-7. PubMed ID: 12411093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid arthritis: a pharmacologic overview.
    Pinals RS
    Am Fam Physician; 1988 Mar; 37(3):145-52. PubMed ID: 2894754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine sulfate in rheumatoid arthritis: long-term response rate and predictive parameters.
    Bell CL
    Am J Med; 1983 Jul; 75(1A):46-51. PubMed ID: 6346870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis.
    Bunch TW; O'Duffy JD; Tompkins RB; O'Fallon WM
    Arthritis Rheum; 1984 Mar; 27(3):267-76. PubMed ID: 6367750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reactions to the principal drugs used in rheumatoid arthritis--a review.
    Franchimont P; Heynen G; Hauwaert CH
    J Rheumatol Suppl; 1978; 4():85-92. PubMed ID: 282449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levamisole in rheumatoid arthritis: a comparison with D-penicillamine.
    Mowat AG; Mowat AM
    J Rheumatol; 1981; 8(4):575-80. PubMed ID: 7299760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis--evaluated in a randomized, parallel 50-week clinical trial.
    Kvien TK; Høyeraal HM; Sandstad B
    J Rheumatol; 1985 Jun; 12(3):533-9. PubMed ID: 3930720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity.
    Prashker MJ; Meenan RF
    Arthritis Rheum; 1995 Mar; 38(3):318-25. PubMed ID: 7880185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow-acting antirheumatic drugs. Drug interactions of clinical significance.
    Munro RA; Sturrock RD
    Drug Saf; 1995 Jul; 13(1):25-30. PubMed ID: 8527017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.
    Ward JR
    Am J Med; 1988 Oct; 85(4A):39-44. PubMed ID: 3052055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying drugs for progressive rheumatoid arthritis.
    Bunch TW; O'Duffy JD
    Mayo Clin Proc; 1980 Mar; 55(3):161-79. PubMed ID: 6766523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the order of second-line treatment in rheumatoid arthritis matter?
    Steven MM; Hunter JA; Murdoch RM; Capell HA
    Br Med J (Clin Res Ed); 1982 Jan; 284(6309):79-81. PubMed ID: 6797663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial.
    Brewer EJ; Giannini EH; Kuzmina N; Alekseev L
    N Engl J Med; 1986 May; 314(20):1269-76. PubMed ID: 3517643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)].
    Warnatz H; Scheiffarth F; Gutmann W
    Med Klin; 1975 Sep; 70(38):1509-15. PubMed ID: 810648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.